Immunic Shares Climb After Guggenheim Starts Coverage with Buy Rating
Immunic Inc. (NASDAQ:IMUX) shares rose 7.7% after Guggenheim initiated coverage with a Buy rating and a $7.00 price target. The analyst cited Phase II evidence in both relapsing and progressive multiple sclerosis, a placebo-like safety profile, and projected Phase III readouts and peak sales assumptions for the company’s oral candidate vidofludimus…